Comparative Pharmacology
Head-to-head clinical analysis: RUXOLITINIB versus VONJO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RUXOLITINIB versus VONJO.
Ruxolitinib vs VONJO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of Janus-associated kinases (JAK) JAK1 and JAK2, reducing cytokine signaling and hematopoiesis.
Pacritinib is a Janus kinase 2 (JAK2) and interleukin-1 receptor-associated kinase 1 (IRAK1) inhibitor. It inhibits JAK2 and mutant JAK2V617F, reducing cytokine signaling and proliferation of malignant cells.
Myelofibrosis: 5-25 mg orally twice daily based on platelet count; Polycythemia Vera: 10 mg orally twice daily; Graft-versus-Host Disease: 5-10 mg orally twice daily.
400 mg orally once daily with food.
None Documented
None Documented
The terminal elimination half-life of ruxolitinib is approximately 3 hours for the parent drug. However, the pharmacodynamic half-life for JAK2 inhibition is longer (up to 8-12 hours) due to sustained target suppression.
Clinical Note
moderateRuxolitinib + Digoxin
"Ruxolitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRuxolitinib + Digitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRuxolitinib + Deslanoside
"Ruxolitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRuxolitinib + Acetyldigitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 40–60 hours; allows once-daily dosing. Steady-state achieved in 8–14 days.
Ruxolitinib is primarily metabolized in the liver, and its metabolites are excreted renally. Approximately 74% of the dose is eliminated in urine (mainly as metabolites) and 22% in feces (as unchanged drug and metabolites).
Primarily metabolized by the liver via CYP3A4 and CYP2C8; ~90% eliminated in feces as metabolites, ~10% in urine as unchanged drug and metabolites.
Category D/X
Category C
JAK Inhibitor
JAK Inhibitor